Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney

Featuring perspectives from Dr Sara M Tolaney, including the following topics: • Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00) • First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13) • First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02) • Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15) CME information and select publications (https://researchtopractice.com/5MJC20...)